Literature DB >> 22821742

External validation of the updated Briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection.

Jens Hansen1, Michael Rink, Marco Bianchi, Luis A Kluth, Zhe Tian, Sascha A Ahyai, Shahrokh F Shariat, Alberto Briganti, Thomas Steuber, Margit Fisch, Markus Graefen, Pierre I Karakiewicz, Felix K-H Chun.   

Abstract

PURPOSE: We aimed to test accuracy and generalizability of a recently updated nomogram to assess the probability of lymph node invasion (LNI), when applied to a different European cohort of men undergoing radical prostatectomy (RP) with extended pelvic lymph node dissection (ePLND).
MATERIALS AND METHODS: The study cohort consisted of 1,282 men with clinically localized PCa who underwent RP and ePLND, including removal of obturator, external iliac, and hypogastric lymph nodes, between 01/2007 and 08/2011. Descriptive measurements included preoperative clinical and biopsy variables, such as prostate-specific antigen (PSA), clinical stage (CS), primary and secondary biopsy Gleason pattern, and percentage of positive cores. We used the area under curve (AUC) of the receiver operator characteristic analysis to quantify accuracy of the model to predict LNI. The extent of over- or under-estimation was explored graphically within loess calibration plots.
RESULTS: The median number of removed lymph nodes was 15 with an interquartile range of 12-20. Twelve percent (n = 155) of men had LNI. Preoperative clinical and biopsy characteristics differed significantly (all P ≤ 0.002) between men with LNI and those without. External validation of the previously reported updated LNI nomogram showed very good accuracy (AUC: 0.829). A nomogram-derived cut-off of 4% could lead to a reduction of 48% of lymph node dissection, while missing 10% of patients with LNI.
CONCLUSIONS: We report the external validation of an updated LNI nomogram, demonstrating accuracy and applicability in a different European cohort. A nomogram-derived cut-off of 4% confirmed good performance characteristics within a different external validation cohort.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22821742     DOI: 10.1002/pros.22559

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  15 in total

1.  Current status of pelvic lymph node dissection in prostate cancer.

Authors:  Ilija Aleksic; Tyler Luthringer; Vladimir Mouraviev; David M Albala
Journal:  J Robot Surg       Date:  2013-12-11

2.  Laparoscopic sentinel lymph node dissection in prostate cancer patients: the additional value depends on preoperative data.

Authors:  Caroline Rousseau; Thierry Rousseau; Cédric Mathieu; Jacques Lacoste; Eric Potiron; Geneviève Aillet; Pierre Nevoux; Georges Le Coguic; Loïc Campion; Françoise Kraeber-Bodéré
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-05-11       Impact factor: 9.236

3.  External evaluation of the Briganti nomogram to predict lymph node metastases in intermediate-risk prostate cancer patients.

Authors:  Nicolas Peilleron; Arnaud Seigneurin; Caroline Herault; Camille Verry; Michel Bolla; Jean-Jacques Rambeaud; Jean-Luc Descotes; Jean-Alexandre Long; Gaelle Fiard
Journal:  World J Urol       Date:  2020-06-24       Impact factor: 4.226

4.  Influence of previous laparo-endoscopic inguinal hernia repair on performing radical prostatectomy: a nationwide survey among urological surgeons.

Authors:  Wouter J Bakker; Marleen M Roos; Richard P Meijer; Josephina P J Burgmans
Journal:  Surg Endosc       Date:  2020-06-02       Impact factor: 4.584

5.  Validation and head-to-head comparison of three nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended and/or sentinel lymph node dissection.

Authors:  Nikolaos Grivas; Esther Wit; Corinne Tillier; Erik van Muilekom; Floris Pos; Alexander Winter; Henk van der Poel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-05       Impact factor: 9.236

6.  Defining the radiobiology of prostate cancer progression: An important question in translational prostate cancer research.

Authors:  Srinivas Vourganti; Jeffrey Donaldson; Linda Johnson; Baris Turkbey; Gennady Bratslavsky; Leszek Kotula
Journal:  Exp Biol Med (Maywood)       Date:  2014-05-30

7.  A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result.

Authors:  M J Donovan; M Noerholm; S Bentink; S Belzer; J Skog; V O'Neill; J S Cochran; G A Brown
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-09-08       Impact factor: 5.554

8.  A clinicogenetic model to predict lymph node invasion by use of genome-based biomarkers from exome arrays in prostate cancer patients.

Authors:  Jong Jin Oh; Seunghyun Park; Sang Eun Lee; Sung Kyu Hong; Sangchul Lee; Hak Min Lee; Jeung Keun Lee; Jin-Nyoung Ho; Sungroh Yoon; Seok-Soo Byun
Journal:  Korean J Urol       Date:  2015-02-02

9.  External Validation of the Briganti Nomogram to Predict Lymph Node Invasion in Prostate Cancer-Setting a New Threshold Value.

Authors:  Bartosz Małkiewicz; Kuba Ptaszkowski; Klaudia Knecht; Adam Gurwin; Karol Wilk; Paweł Kiełb; Krzysztof Dudek; Romuald Zdrojowy
Journal:  Life (Basel)       Date:  2021-05-25

10.  Validation of a rectal cancer outcome prediction model with a cohort of Chinese patients.

Authors:  Lijun Shen; Johan van Soest; Jiazhou Wang; Jialu Yu; Weigang Hu; Yutao U T Gong; Vincenzo Valentini; Ying Xiao; Andre Dekker; Zhen Zhang
Journal:  Oncotarget       Date:  2015-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.